COVID-19-Associated Pulmonary Aspergillosis (CAPA) in Northern Greece during 2020-2022: A Comparative Study According to the Main Consensus Criteria and Definitions.
SARS-CoV-2 pandemic
coronavirus disease 2019-associated pulmonary aspergillosis (CAPA)
criteria
definitions
diagnosis
invasive pulmonary aspergillosis
mycology laboratory
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
27
11
2022
revised:
01
01
2023
accepted:
03
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) has emerged as an important complication among patients with acute respiratory failure due to SARS-CoV-2 infection. Almost 2.5 years since the start of the COVID-19 pandemic, it continues to raise concerns as an extra factor that contributes to increased mortality, which is mostly because its diagnosis and management remain challenging. The present study utilises the cases of forty-three patients hospitalised between August 2020 and February 2022 whose information was gathered from ten ICUs and special care units based in northern Greece. The main aim was to describe the gained experience in diagnosing CAPA, according to the implementation of the main existing diagnostic consensus criteria and definitions, and present the different classification of the clinical cases due to the alternative algorithms.
Identifiants
pubmed: 36675902
pii: jof9010081
doi: 10.3390/jof9010081
pmc: PMC9863007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Clin Microbiol Infect. 2022 Apr;28(4):580-587
pubmed: 34454093
Med Mycol Case Rep. 2021 Mar;31:2-5
pubmed: 32395423
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
J Crit Care. 2020 Oct;59:149-155
pubmed: 32674001
J Fungi (Basel). 2022 Jan 19;8(2):
pubmed: 35205852
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Am J Respir Crit Care Med. 2008 Jan 1;177(1):27-34
pubmed: 17885264
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
Intensive Care Med. 2021 Aug;47(8):819-834
pubmed: 34160631
J Fungi (Basel). 2020 Jun 24;6(2):
pubmed: 32599813
J Fungi (Basel). 2020 Jul 10;6(3):
pubmed: 32664423
Ann Intensive Care. 2020 Jun 1;10(1):71
pubmed: 32488446
Lancet Infect Dis. 2021 Jun;21(6):767
pubmed: 33662326
Lancet Microbe. 2020 Jun;1(2):e53-e55
pubmed: 32835328
Emerg Infect Dis. 2021;27(4):1077-1086
pubmed: 33539721
Mycoses. 2020 Dec;63(12):1368-1372
pubmed: 32965042
Ann Med Surg (Lond). 2021 Sep;69:102816
pubmed: 34512964
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Mycoses. 2019 Mar;62(3):230-236
pubmed: 30565352
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644
pubmed: 32860682
Mycoses. 2020 Aug 4;:
pubmed: 32749040
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Clin Infect Dis. 2007 Jul 15;45(2):205-16
pubmed: 17578780
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30936100
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33084566
Signal Transduct Target Ther. 2020 Jul 25;5(1):128
pubmed: 32712629
Crit Care. 2016 May 10;20(1):139
pubmed: 27160692
Clin Microbiol Infect. 2021 Sep;27(9):1230-1241
pubmed: 33601011
Lancet Infect Dis. 2021 Jun;21(6):767-769
pubmed: 33662323
Pathogens. 2021 Oct 22;10(11):
pubmed: 34832526
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Clin Infect Dis. 2021 Oct 5;73(7):e1645-e1648
pubmed: 32887998